Viking Therapeutics, Inc. (VKTX) income statement
VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.17−0.71 (-2.64%)
Close on Nov 18, 2026Market cap $3.34BP/E –Yield –
Viking Therapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -47.3%
Financial strength
- Current ratio
- 7.27
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 506.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.67
- Dividend yield
- –
See a number that looks wrong?